Table 2 Enriched pathways of the upregulated phosphoproteins (fold change >1.5) in HuH-7R cells by DAVID based on KEGG pathways.

From: Quantitative phosphoproteomic analysis identifies the potential therapeutic target EphA2 for overcoming sorafenib resistance in hepatocellular carcinoma cells

Enriched pathway

−Log (p value)

Molecules

Gap junction

6.262012674

RAF1, CDK1, EGFR, ITPR3, MAPK1, MAP3K2, TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3E, TUBB2A, TUBB2B, TUBB3, TUBB4B

Regulation of actin cytoskeleton

5.018181393

CRK, GIT1, IQGAP1, RAF1, ACTB, ACTG1, ARPC1B, CFL1, CFL2, EGFR, ITGA3, MAPK1, MSN, PAK4, PXN, PPP1CA, PPP1R12A, PPP1R12C, RRAS2, SSH2, VCL

Focal adhesion

3.568636236

CRK, MET, RAF1, ACTB, ACTG1, EGFR, FLNA, FLNB, ITGA3, MAPK1, PAK4, PXN, PPP1CA, PPP1R12A, PPP1R12C, TLN1, VCL, ZYX

Adherens junction

3.432973634

IQGAP1, MET, ACTB, ACTG1, CTNNA1, CTNNA2, EGFR, MAPK1, MAP3K7, VCL

mTOR signaling pathway

2.657577319

AKT1S1, RICTOR, RRAGC, MAPK1, PRKAA1, RPTOR, RPS6KA1, RPS6

MAPK signaling pathway

2.568636236

CRK, RAF1, CDC25B, DAXX, EGFR, FLNA, FLNB, HSPA1A, HSPB1, MAPT, MAPK1, MAP3K2, MAP3K7, NF1, RRAS2, RPS6KA1, STMN1, ZAK

Rap1 signaling pathway

1.795880017

CRK, EPHA2, MET, RAP1GAP, RAF1, RAPGEF6, ACTB, ACTG1, EGFR, MAPK1, PRKD1, PRKD2, SIPA1, TLN1

  1. Membrane receptors are specifically marked in bold.